TY  - JOUR
AU  - Pavlović, Marijana
AU  - Kahrović, Emira
AU  - Aranđelović, Sandra
AU  - Radulović, Siniša
AU  - Ilich, Predrag-Peter
AU  - Grgurić-Šipka, Sanja
AU  - Ljubijankić, Nevzeta
AU  - Žilić, Dijana
AU  - Jurec, Jurica
PY  - 2023
UR  - http://cherry.chem.bg.ac.rs/handle/123456789/5901
AB  - Novel ruthenium(III) complexes of general formula Na[
RuCl2(L1−3-N,O)2] where L(
1–3) denote deprotonated Schiff bases
(
HL1-HL3) derived from 5-substituted salicyladehyde and alkylamine (propyl- or butylamine) were prepared and characterized
based on elemental analysis, mass spectra, infrared, electron spin/paramagnetic resonance (ESR/EPR) spectroscopy,
and cyclovoltammetric study. Optimization of five isomers of complex C1 was done by DFT calculation. The interaction
of C1–C3 complexes with DNA (Deoxyribonucleic acid) and BSA (Bovine serum albumin) was investigated by electron
spectroscopy and fluorescence quenching. The cytotoxic activity of C1–C3 was investigated in a panel of four human cancer
cell lines (K562, A549, EA.hy926, MDA-MB-231) and one human non-tumor cell line (MRC-5). Complexes displayed an
apparent cytoselective profile, with IC50
values in the low micromolar range from 1.6 ± 0.3 to 23.0 ± 0.1 μM. Cisplatinresistant
triple-negative breast cancer cells MDA-MB-231 displayed the highest sensitivity to complexes, with Ru(III)
compound containing two chlorides and two deprotonated N-propyl-5-chloro-salicylidenimine (hereinafter C1) as the most
potent (
IC50 = 1.6 μM), and approximately ten times more active than cisplatin (
IC50 = 21.9 μM). MDA-MB-231 cells treated
for 24 h with C1 presented with apoptotic morphology, as seen by acridine orange/ethidium bromide staining, while 48 h of
treatment induced DNA fragmentation, and necrotic changes in cells, as seen by flow cytometry analysis. Drug-accumulation
study by inductively coupled plasma mass spectrometry (ICP-MS) demonstrated markedly higher intracellular accumulation
of C1 compared with cisplatin.
PB  - Springer
T2  - J. Biol. Inorg. Chem.
T1  - Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells
VL  - 28
SP  - 263
EP  - 284
DO  - 10.1007/s00775-023-01989-0
ER  - 

@article{
author = "Pavlović, Marijana and Kahrović, Emira and Aranđelović, Sandra and Radulović, Siniša and Ilich, Predrag-Peter and Grgurić-Šipka, Sanja and Ljubijankić, Nevzeta and Žilić, Dijana and Jurec, Jurica",
year = "2023",
abstract = "Novel ruthenium(III) complexes of general formula Na[
RuCl2(L1−3-N,O)2] where L(
1–3) denote deprotonated Schiff bases
(
HL1-HL3) derived from 5-substituted salicyladehyde and alkylamine (propyl- or butylamine) were prepared and characterized
based on elemental analysis, mass spectra, infrared, electron spin/paramagnetic resonance (ESR/EPR) spectroscopy,
and cyclovoltammetric study. Optimization of five isomers of complex C1 was done by DFT calculation. The interaction
of C1–C3 complexes with DNA (Deoxyribonucleic acid) and BSA (Bovine serum albumin) was investigated by electron
spectroscopy and fluorescence quenching. The cytotoxic activity of C1–C3 was investigated in a panel of four human cancer
cell lines (K562, A549, EA.hy926, MDA-MB-231) and one human non-tumor cell line (MRC-5). Complexes displayed an
apparent cytoselective profile, with IC50
values in the low micromolar range from 1.6 ± 0.3 to 23.0 ± 0.1 μM. Cisplatinresistant
triple-negative breast cancer cells MDA-MB-231 displayed the highest sensitivity to complexes, with Ru(III)
compound containing two chlorides and two deprotonated N-propyl-5-chloro-salicylidenimine (hereinafter C1) as the most
potent (
IC50 = 1.6 μM), and approximately ten times more active than cisplatin (
IC50 = 21.9 μM). MDA-MB-231 cells treated
for 24 h with C1 presented with apoptotic morphology, as seen by acridine orange/ethidium bromide staining, while 48 h of
treatment induced DNA fragmentation, and necrotic changes in cells, as seen by flow cytometry analysis. Drug-accumulation
study by inductively coupled plasma mass spectrometry (ICP-MS) demonstrated markedly higher intracellular accumulation
of C1 compared with cisplatin.",
publisher = "Springer",
journal = "J. Biol. Inorg. Chem.",
title = "Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells",
volume = "28",
pages = "263-284",
doi = "10.1007/s00775-023-01989-0"
}

Pavlović, M., Kahrović, E., Aranđelović, S., Radulović, S., Ilich, P., Grgurić-Šipka, S., Ljubijankić, N., Žilić, D.,& Jurec, J.. (2023). Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells. in J. Biol. Inorg. Chem.
Springer., 28, 263-284.
https://doi.org/10.1007/s00775-023-01989-0

Pavlović M, Kahrović E, Aranđelović S, Radulović S, Ilich P, Grgurić-Šipka S, Ljubijankić N, Žilić D, Jurec J. Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells. in J. Biol. Inorg. Chem.. 2023;28:263-284.
doi:10.1007/s00775-023-01989-0 .

Pavlović, Marijana, Kahrović, Emira, Aranđelović, Sandra, Radulović, Siniša, Ilich, Predrag-Peter, Grgurić-Šipka, Sanja, Ljubijankić, Nevzeta, Žilić, Dijana, Jurec, Jurica, "Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells" in J. Biol. Inorg. Chem., 28 (2023):263-284,
https://doi.org/10.1007/s00775-023-01989-0 . .

TY  - JOUR
AU  - Ljubijankić, Nevzeta
AU  - Stanković, Miomir
AU  - Tešević, Vele
AU  - Grgurić-Šipka, Sanja
AU  - Jadranin, Milka
AU  - Begić, Sabina
AU  - Šabanović, Elma
PY  - 2018
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/332
AB  - This study evaluates the genotoxic potential of two Ru(III) complexes with thiosemicarbazone based ligands. The complexes were tested for in vitro protective effect on chromosome aberrations in peripheral human lymphocytes using the cytokinesis block micronucleus (CBMN) assay at concentrations 1.5; 3.7 and 7.4 μg/mL. The cell culture treated with the tested complexes, at 3.7 μg/mL concentration, decreased a frequency of micronucleus for 37% and 32%, when compared with the control cell cultures. At concentration of 7.4 (1.5) μg/mL of this complexes exhibited slightly lower effect of micronucleus for 30% (35%) and 27% (29%), when compared with the control cell cultures. © RASĀYAN. All rights reserved.
T2  - Rasayan Journal of Chemistry
T1  - Cytokinesis block micronucleus assay in human lymphocytes after exposure to Ru(III) thiosemicarbazone complexes in vitro
VL  - 11
IS  - 2
SP  - 647
EP  - 652
DO  - 10.31788/rjc.2018.1123004
ER  - 

@article{
author = "Ljubijankić, Nevzeta and Stanković, Miomir and Tešević, Vele and Grgurić-Šipka, Sanja and Jadranin, Milka and Begić, Sabina and Šabanović, Elma",
year = "2018",
abstract = "This study evaluates the genotoxic potential of two Ru(III) complexes with thiosemicarbazone based ligands. The complexes were tested for in vitro protective effect on chromosome aberrations in peripheral human lymphocytes using the cytokinesis block micronucleus (CBMN) assay at concentrations 1.5; 3.7 and 7.4 μg/mL. The cell culture treated with the tested complexes, at 3.7 μg/mL concentration, decreased a frequency of micronucleus for 37% and 32%, when compared with the control cell cultures. At concentration of 7.4 (1.5) μg/mL of this complexes exhibited slightly lower effect of micronucleus for 30% (35%) and 27% (29%), when compared with the control cell cultures. © RASĀYAN. All rights reserved.",
journal = "Rasayan Journal of Chemistry",
title = "Cytokinesis block micronucleus assay in human lymphocytes after exposure to Ru(III) thiosemicarbazone complexes in vitro",
volume = "11",
number = "2",
pages = "647-652",
doi = "10.31788/rjc.2018.1123004"
}

Ljubijankić, N., Stanković, M., Tešević, V., Grgurić-Šipka, S., Jadranin, M., Begić, S.,& Šabanović, E.. (2018). Cytokinesis block micronucleus assay in human lymphocytes after exposure to Ru(III) thiosemicarbazone complexes in vitro. in Rasayan Journal of Chemistry, 11(2), 647-652.
https://doi.org/10.31788/rjc.2018.1123004

Ljubijankić N, Stanković M, Tešević V, Grgurić-Šipka S, Jadranin M, Begić S, Šabanović E. Cytokinesis block micronucleus assay in human lymphocytes after exposure to Ru(III) thiosemicarbazone complexes in vitro. in Rasayan Journal of Chemistry. 2018;11(2):647-652.
doi:10.31788/rjc.2018.1123004 .

Ljubijankić, Nevzeta, Stanković, Miomir, Tešević, Vele, Grgurić-Šipka, Sanja, Jadranin, Milka, Begić, Sabina, Šabanović, Elma, "Cytokinesis block micronucleus assay in human lymphocytes after exposure to Ru(III) thiosemicarbazone complexes in vitro" in Rasayan Journal of Chemistry, 11, no. 2 (2018):647-652,
https://doi.org/10.31788/rjc.2018.1123004 . .